Genetic abnormalities in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia

Medical Oncology

Volumn 15, Issue 2, 1998, Pages 79-88

  Merup, Mats ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chronic lymphocytic leukemia; Cytogenetics; FISH; Genetics; Non Hodgkin's lymphoma; Oncogenes

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; DNA; GENE PRODUCT; PHOSPHOTRANSFERASE; PROTEIN BCL 2; PROTEIN P16; PROTEIN P53;

CELL SURVIVAL; CHROMOSOME 13Q; CHROMOSOME 6Q; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 2; CHROMOSOME TRANSLOCATION 9; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; DNA REPAIR; GENE FUSION; GENETIC DISORDER; HUMAN; NONHODGKIN LYMPHOMA; ONCOGENE; ONCOGENE C MYC; PRIORITY JOURNAL; REVIEW; TRISOMY; TUMOR SUPPRESSOR GENE;

EID: 0031680721     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02989584     Document Type: Review

References (87)

1. Caspersson T, Zech L, Johansson C. Differential binding of alkylating fluorochromes in human chromosomes. Exp Cell Res 1970; 60: 315-319.
2. Korsmeyer SJ. Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. Annu Rev Immunol 1994; 10: 785-807.
3. Boxer LM. The role of oncogenes in hematologic malignancies. Annu Rev Med 1994; 45: 1-11.
4. Boehm T, Rabbitts TH. The human T cell receptor genes are targets for chromosomal abnormalities in T cell tumors. FASEB J 1989; 3: 2344-2359.
5. Williams ME, Swerdlow SH, Rosenberg CL, Arnold A. Chromosome 11 translocation breakpoint at the PRAD1/ cyclin D1 gene locus in centrocytic lymphoma. Leukemia 1993; 7: 241
6. Morris SW, Kirstein MN, Valentine MB. Fusion of a kinase gene, ALK, to a nucleolar protein, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-1284.
7. Lotem J, Sachs L. Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. Leukemia 1996; 10: 925-931.
8. Arends MJ, Wyllie AH. Apoptosis: Mechanisms and roles in pathology. Int Rev Exp Pathol 1991; 32: 223.
9. D'Amico A, Gillies McKenna W. Apoptosis and a re-investigation of the biologic basis for cancer therapy. Radiother 1994; 33: 3-10.
10. White E, Cipriani R, Sabbatini P, Denton A. Adenovirus E1B19-kilodalton protein overcomes the cytoxicity of E1A proteins. J Virol 1991; 65: 2968-2972.
11. Lotem J, Sachs L. Regulation of bcl-2, c-myc and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation competent and defective myeloid leukemic cells. Cell Growth Differ 1993; 4: 41.
12. Goldstein P, Ojcius DM, Young D-E. Cell death mechanism and the immune system. Immunol Rev 1991; 121: 29.
13. Yonish-Rouach E et al. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin 6. Nature 1991; 352: 345.
14. Neubauer A, Thiede C, Huhn D, Wittig B. Alterations of the retinoblastoma a susceptibility gene in chronic lymphocytic leukemia. Leuk Lymphoma 1996; 18: 399-404.
15. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 1996; 335(22): 1643-1649.
16. Watanabe Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314-317.
17. Robertson LO et al. Induction of DNA cleavage in chronic lymphocytic leukemic cells by chlorodeoxyadenosine and fludarabine. Proc Am Assoc Cancer Res 1991; 32: 98.
18. Robertson L et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′deoxyadenosine and 9-β-D-arabinosyl-2-fluoro-adenine. Blood 1993; 81: 143-150.
19. Knudson AG. Mutation and cancer. Statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820.
20. Cordon-Cardo C, Dalbagni G, Richon VM. Significance of the retinoblastoma gene in human cancer. Principles & Practice of Oncology 1992; 6: 1-9.
21. Harbour JW et al. Abnormalities in structure and expression of the human retinoblastoma gene in small cell lung cancer. Science 1988; 241: 353.
22. Kolodner RD. Mismatch repair: mechanisms and relationship to cancer susceptibility. Trends Biochem Sci 1995; 20: 397-401.
23. Rayssiguier C, Thaler DS, Radman M. The barrier to recombination between Escherichia coli AND Salmonella typhimurium is disrupted in mismatch-repair mutants. Nature 1989; 342: 396-401.
24. Hawn MT et al. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res 1995; 55: 3721-3725.
25. Mellon I, Rajpal DK, Koi M, Boland CR, Champe GN. Transcription-coupled repair deficiency and mutations in human mismatch repair genes. Science 1996; 272: 557-560.
26. Bedi GC, Westra WH, Farzadegan H, Pitha PM, Sidransky D. Microsatelite instability in primary neoplasms from HIV+ patients. Nat Med 1995; 1: 65.
27. Larsson RS, Scott MA, McCurley TL, Wnencak-Jones CL. Microsatellite analysis of posttransplant lymphoproliferative disorders; determination of donor/recipient origin and identification of putative lymphomagenic mechanism. Cancer Res 1996; 56: 4378-4381.
28. Gartenhaus R, Johns III MM, Wang P, Rai K, Sidransky D. Mutator phenotype in a subset of chronic lymphocytic leukemia. Blood 1996; 87: 38-41.
29. Juliusson G et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990; 323: 720-724.
30. Criel A et al. Trisomy 12 is uncommon in typical chronic lymphocytic leukaemias. Br J Haematol 1994; 87: 523-528.
31. Garcia-Marco J et al. Correlation of trisomy 12 with proliferating cells by combined immunocytochemistry and fluorescence in situ hybridization in chronic lymphocytic leukaemia. Leukemia 1996; 9: 2140-2146.
32. Escudier SM et al. Fluorescence in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia. Blood 1993; 81: 2702-2707.
33. Dierlamm J et al. FISH identifies different types of duplications with 12q13-15 as the commonly involved segment in B-cell lymphoproliferative malignancies characterized by partial trisomy 12. Genes Chromosomes Cancer 1997; 20: 155-166.
34. Merup M et al. Amplification of multiple regions of chromosome 12, including 12q13-15, in chronic lymphocytic leukaemia. Eur J Haematol 1997; 58: 174-180.
35. Oscier DG. Cytogenetic and molecular abnormalities in chronic lymphocytic leukaemia. Blood Rev 1994; 8: 88-97.
36. Liu Y et al. Chronic lymphocytic leukemia cells with allelic deletions at 13q14 commonly have one intact RB1 gene: Evidence for a role of an adjacent locus. Proc Natl Acad Sci USA 1993; 90: 8697-8701.
37. Liu Y et al. 13q deletions in lymphoid malignancies. Frequency of deletions in various diseases and characterization of the minimal region of overlap for the genetic loss. Blood 1995; 86: 1911-1915.
38. Liu Y et al. Cloning of two candidate tumor suppressor genes within a 10kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia. Oncogene 1997; 15: 2463-2473.
39. Garcia-Marco JA et al. Frequent somatic deletion of the 13q12.3 encompassing BRCA2 in chronic lymphocytic leukemia. Blood 1996; 88: 1568-1575.
40. Panayiotidis P et al. Deletion of 13q14.3 and not 13q12 is the most common genetic abnormality detected in chronic lymphocytic leukemia cells. Blood 1997; 89: 734-735.
41. Offit K, Jhanwar SC, Ladanyi M, Filippa DA, Chaganti RSK. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment. Genes Chromosomes Cancer 1991; 3: 189-201.
42. Gaidano G et al. Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. Blood 1992; 80: 1781-1787.
43. Offit K et al. Clinical and morphologic features of B-cell small lymphocytic lymphoma with del(6)(q21q23). Blood 1994; 83: 2611-2618.
44. Johansson B, Mertens F, Mitelman F. Cytogenetic evolution patterns in non-Hodgkin's lymphoma. Blood 1995; 86: 3905-3914.
45. Le Beau MM et al. The t(2;5)(p23;q35); a recurring chromosomal abnormality in Ki-1 + anaplastic large cell lymphoma. Leukemia 1989; 3: 866-870.
46. Lamant L et al. High incidence of the t(2;5) (p23;q35) (translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, RT-PCR and P80 immunostaining. Blood 1996; 87: 284-291.
47. Orscheschek K et al. Large-cell anaplastic lymphoma-specific translocation (t[2;5][p23;q35] in Hodgkin's disease: indication of a common pathogenesis? Lancet 1995; 345: 87-90.
48. Weisenburger DD, Armitage JO. Mantel cell lymphoma - an entity comes of age. Blood 1996; 87: 4483-4494.
49. Bosch F et al. PRAD1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994; 84: 2726.
50. Hunter T, Pines J. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573.
51. Daudy SF et al. Physical interactions of the retinoblastoma protein with human D cyclins. Cell 1993; 73: 499.
52. Offit K et al. Clusters of chromosome 9 aberrations are associated with clinico-pathologic subset of non-Hodgkin's lymphoma. Genes Chromosomes Cancer 1993; 7: 1.
53. Harris NL et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International lymphoma study group. Blood 1994; 84: 1361-1392.
54. Iida S et al. The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood 1996; 88: 4110-4141.
55. Stuart ET, Haffner R, Oren M, Gruss P. Loss of p53 function through PAX-mediated transcriptional repression. EMBO 1995; 14: 5638.
56. Mitelman F, Heim S. Cancer Cytogenetics. Chromosomal and Molecular Genetic Aberrations of Tumour Cells Second edition. 1995; Wiley-Liss, New York.
57. McDonnel TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade lymphoma in mice transgenic for the t(14;18). Nature 1991; 349: 6306.
58. Bastard C et al. Translocations involving band 3q27 and Ig gene regions in non-Hodgkin's lymphoma. Blood 1992; 79: 2527-2531.
59. Ye BH et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J 1995; 14: 6209-6217.
60. Bastard C et al. LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood 1994; 83: 2423-2427.
61. Gaidano G et al. Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrom-associated non-Hodgkin's lymphoma: association with diffuese large-cell subtype. Blood 1994; 84: 397-402.
62. Serrano M, Hannon G, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707.
63. Koduru PRK et al. Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma. Blood 1995; 86: 2900-2905.
64. Yunis JJ et al. Multiple recurrent genomic defects in follicular lymphoma. N Engl J Med 1987; 316: 79.
65. Cleary M, Galili N, Sklar J. Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas. J Exp Med 1986; 164: 315-320.
66. Adachi M, Tefferi A, Greipp P, Kipps T, Tsujimoto Y. Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukaemia. J Exp Med 1990; 171: 559-564.
67. Merup M et al. Bcl-2 rearrangements with breakpoints in both vcr and mbr in non-Hodgkin lymphomas. Br J Haematol 1996; 92: 647-652.
68. Tang SC, Visser L, Hepperle B, Hanson J, Poppema S. Clinical significance of bcl-2-mbr gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: An analysis of 83 cases. J Clin Oncol 1994; 12: 149-154.
69. Isaacson PG, Wotherspoon AC, Diss TC, Pan LX. Bcl-2 expression in lymphomas. Lancet 1991; 337: 175-176.
70. Pettersson M et al. Expression of the bcl-2-gene in human multiple myeloma cell lines and normal plasma cells. Blood 1992; 79: 495-502.
71. Ngan B, Zehava C, Weiss L, Warnke RA, Cleary M. Expression in non-Hodgkin's lymphoma of the bcl-2-protein associated with the t(14,18) chromosomal translocation. N Engl J Med 1988; 25: 1638-1644.
72. Yano T, Jaffe ES, Longo DL, Raffeld M. MYC rearrangements in histologically progressed follicular lymphomas. Blood 1992; 80: 758.
73. Sander CA et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82: 1994-2004.
74. Matolcsy A, Casali P, Warnke RA, Knowles DM. Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated bcl-2 gene. Blood 1996; 88: 3937-3944.
75. H rearrangements in benign Iymphoid tissues with follicular hyperplasia. Oncogene 1991; 6: 2271.
76. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 1992; 80: 879.
77. Batistatou A, Merry DE, Korsmeyer SJ, Green LA. Expression of Bcl-2 proto-oncogene rescues PC12 cells from death caused by withdrawal of trophic support. J Neurosci 1993; 13: 4422.
78. Rao L et al. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kilodalton protein with Bcl-2 proteins. Proc Natl Acad Sci USA 1992; 89: 7742.
79. Imamura J, Miyoshi I, Koeffler HP. p53 in hematologic malignancies. Blood 1994; 84: 2412-2421.
80. Kern SE et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992; 256: 827-830.
81. Clarke AR et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362: 849-852.
82. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-852.
83. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996; 10: 1054-1072.
84. Oren M. p53: the ultimate tumor suppressor gene? FASEB J 1992; 6: 3169-3176.
85. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523-526.
86. Wattel E et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148-3157.
87. Lo Coco F et al. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82: 2289-2295.